Timeline

Dr. Harlan Robins, professor at the Fred Hutchinson Cancer Research Institute, and colleagues develop the first immunosequencing technology to profile the T-cell immune repertoire at scale and with precision, which had never before been possible.

Adaptive launches its first research product, immunoSEQ. Scientists worldwide now have this sophisticated tool to profile and monitor the adaptive immune response, to propel their research in many diseases, and to understand the immune response to therapies. “We have delivered the Hubble Telescope as compared to a pair of binoculars to look at the adaptive immune system.” Chad Robins, Chief Executive Officer, Co-founder, Chairman of the Board

Adaptive’s technology propels research forward in oncology, hematology, infectious disease, transplantation, and autoimmunity, enabling a paradigm shift in understanding human immunology.

Chad and Harlan are honored by Goldman Sachs for their groundbreaking technology and the promise Adaptive can bring to the future of medicine.

Adaptive reaches 200 publications based on our technology.

clonoSEQ receives FDA clearance for the detection and monitoring of measurable residual disease (MRD) in patients with multiple myeloma and acute lymphoblastic leukemia.

Patients with certain blood cancers are ensured access by Medicare for MRD assessment to support more personalized treatment decisions. This paves the way for further coverage by private payers.  

From narcolepsy to ovarian cancer. From HIV to SARS-CoV-2. From the healthy baseline of the immune repertoire to kidney transplantation. Adaptive continues to propel the understanding of the smallest details and the biggest insights of immune response.

Adaptive launches immunoSEQ T-MAP COVID, a new tool for researchers that measures the T-cell response to vaccines in development and tracks the persistence of the responses over time.

Adaptive launches T-Detect COVID, a novel diagnostic test for patients that uses the T cell as a marker to indicate recent or past infection. This is a small step for Adaptive and a large step towards Adaptive’s and Microsoft’s ultimate vision to develop T cell–based tests for early and accurate detection of many diseases from a single blood sample.